Andexanet Alfa Vs. Four-Factor PCC: Is Andexanet Alfa Worth The Hype?
Background: Oral factor Xa inhibitors (FXi) have been associated with major and fatal bleeding events, including intracranial hemorrhage (ICH). In randomized controlled trials, both rivaroxaban and apixaban are associated with ICH at rates that range from 0.1 to 4% (Agnelli 2013, Granger 2011, Investigators 2010, Patel 2011). While these studies did not specifically set out … Continue reading Andexanet Alfa Vs. Four-Factor PCC: Is Andexanet Alfa Worth The Hype?
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed